PTCHF catalyst calendar

PureTech Health plc

Upcoming catalysts
1
Phase 3 programs
1

PureTech Health plc is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) on November 15, 2029. There is 1 upcoming event on record.

Across 7 concluded trials, 71% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 15, 2029 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) Trial Milestone Phase 3

Track PTCHF alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open PTCHF in the tracker

Recent history

DateEventTypePhase
May 1, 2026 6-K filed: Foreign issuer report Filing —
April 29, 2026 6-K filed: Foreign issuer report Filing —
April 29, 2026 6-K filed: Foreign issuer report Filing —
April 29, 2026 Results filed (20-F) Earnings —
December 31, 2025 A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) Trial Milestone Phase 1
December 18, 2025 6-K filed: Foreign issuer report Filing —
December 10, 2025 6-K filed: Foreign issuer report Filing —
August 28, 2025 6-K filed: Foreign issuer report Filing —
July 16, 2025 6-K filed: Foreign issuer report Filing —
July 8, 2025 6-K filed: Foreign issuer report Filing —
June 16, 2025 6-K filed: Foreign issuer report Filing —
April 30, 2025 6-K filed: Foreign issuer report Filing —
April 30, 2025 Results filed (20-F) Earnings —
February 17, 2025 Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib Trial Milestone Phase 1
December 12, 2024 LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors Trial Milestone Phase 1/Phase 2
October 15, 2024 LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Trial Milestone Phase 2
October 18, 2023 LYT-300 in Healthy Volunteers Trial Milestone Phase 1/Phase 2
September 9, 2022 LYT-100 in Patients With BCRL Trial Milestone Phase 2
June 28, 2022 LYT-100 in Post-acute COVID-19 Respiratory Disease Trial Milestone Phase 2
January 1, 2022 PK of Deupirfenidone Versus Pirfenidone in Older Healthy Subjects Trial Milestone Phase 1

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.